Why Is Carlsmed Stock Gaining Monday? - Carlsmed ( NASDAQ:CARL )
CMS grants NTAP reimbursement of up to $21,125 for Carlsmed's spine implants. BofA forecasts 66% revenue growth in 2025, Buy rating with $16 target. Get the exact trades and sectors to target before August's biggest earnings-driven market moves. Details here → Carlsmed Inc.
ISRG's Ion Platform Procedure Grows 52%: Can This Trend Continue?
Intuitive Surgical's Ion platform saw Q2 procedures jump 52% to 35,000, expanding globally as utilization rises despite softer system placements.
Globus Medical Stock Up on Q2 Earnings & Revenue Beat, Margins Expand
GMED posts strong Q2 with earnings and revenues, boosted by the Nevro acquisition and expanded margins.
Why This 1 Value Stock Could Be a Great Addition to Your Portfolio
The Zacks Style Scores offers investors a way to easily find top-rated stocks based on their investing style. Here's why you should take advantage.
Globus Medical ( GMED ) Q2 Revenue Up 18%
Globus Medical ( NYSE:GMED ) , a spinal and musculoskeletal medical device company, reported its Q2 2025 earnings on August 7, 2025. The main highlight was a jump in headline net income ( GAAP ) in Q2 2025, driven by unique, non-operational items such as a major acquisition gain and a one-time ...
Globus Medical ( GMED ) Beats Q2 Earnings and Revenue Estimates
Globus Medical (GMED) delivered earnings and revenue surprises of +13.16% and +0.49%, respectively, for the quarter ended June 2025. Do the numbers hold clues to what lies ahead for the stock?
Globus Medical Reports Second Quarter 2025 Results
AUDUBON, Pa., Aug. 07, 2025 ( GLOBE NEWSWIRE ) -- Globus Medical, Inc. ( NYSE: GMED ) , a leading musculoskeletal solutions company, today announced its financial results for the quarter ended June 30, 2025.
Stay Ahead of the Game With Globus Medical ( GMED ) Q2 Earnings: Wall Street's Insights on Key Metrics
Looking beyond Wall Street's top-and-bottom-line estimate forecasts for Globus Medical (GMED), delve into some of its key metrics to gain a deeper insight into the company's potential performance for the quarter ended June 2025.
LivaNova ( LIVN ) Q2 Earnings and Revenues Beat Estimates
LivaNova (LIVN) delivered earnings and revenue surprises of +25.00% and +6.56%, respectively, for the quarter ended June 2025. Do the numbers hold clues to what lies ahead for the stock?
Globus Medical ( GMED ) Reports Next Week: Wall Street Expects Earnings Growth
Globus Medical (GMED) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
How Is The Market Feeling About Globus Medical? - Globus Medical ( NYSE:GMED )
Globus Medical's GMED short percent of float has risen 4.92% since its last report. The company recently reported that it has 4.52 million shares sold short, which is 4.48% of all regular shares that are available for trading.
Can ISRG's Strong Q2 Procedure Volume Translate Into Durable EPS Upside?
ISRG's Q2 procedure growth hits 17%, but continuation of EPS growth hinges on easing margin pressure from FX and da Vinci 5 adoption.
Dentsply Sirona Appoints Daniel Scavilla as Chief Executive Officer
Provides Select Preliminary Second Quarter 2025 Results and Reaffirms 2025 Outlook Provides Select Preliminary Second Quarter 2025 Results and Reaffirms 2025 Outlook ...
Dentsply Sirona Appoints Daniel Scavilla as Chief Executive Officer - Globus Medical ( NYSE:GMED ) , Dentsply Sirona ( NASDAQ:XRAY )
CHARLOTTE, N.C., July 21, 2025 ( GLOBE NEWSWIRE ) -- DENTSPLY SIRONA Inc. ( "Dentsply Sirona" or "the Company" ) XRAY today announced that Daniel Scavilla, an established business leader with more than three decades of experience in the medical technology and pharmaceutical industries and a ...
Globus Medical Announces Leadership Transitions and Preliminary Second Quarter 2025 Sales Results
AUDUBON, Pa., July 21, 2025 ( GLOBE NEWSWIRE ) -- Globus Medical, Inc. ( NYSE: GMED ) , a leading musculoskeletal technology company, today announced that Keith Pfeil, Executive Vice President, Chief Operating Officer and Chief Financial Officer, has been appointed President and Chief Executive ...
Globus Medical Announces Leadership Transitions and Preliminary Second Quarter 2025 Sales Results - Globus Medical ( NYSE:GMED )
AUDUBON, Pa., July 21, 2025 ( GLOBE NEWSWIRE ) -- Globus Medical, Inc. GMED, a leading musculoskeletal technology company, today announced that Keith Pfeil, Executive Vice President, Chief Operating Officer and Chief Financial Officer, has been appointed President and Chief Executive Officer ...
Globus Medical Schedules Second Quarter Earnings Release and Conference Call - Globus Medical ( NYSE:GMED )
AUDUBON, Pa., July 17, 2025 ( GLOBE NEWSWIRE ) -- Globus Medical, Inc. GMED, a leading musculoskeletal technology company, will announce its financial results for the second quarter ended June 30, 2025 after the market close on Thursday, August 7, 2025.
Globus Medical Schedules Second Quarter Earnings Release and Conference Call
AUDUBON, Pa., July 17, 2025 ( GLOBE NEWSWIRE ) -- Globus Medical, Inc. ( NYSE:GMED ) , a leading musculoskeletal technology company, will announce its financial results for the second quarter ended June 30, 2025 after the market close on Thursday, August 7, 2025.
GMED Unveils Next-Gen Oscillating System DuraPro: Stock to Gain?
Globus Medical debuts DuraPro with Excelsius integration, boosting its Power Portfolio.
Globus Medical Introduces DuraPro™ with Navigation, a Next-Generation, Oscillating System Designed to Safeguard Delicate Tissue - Globus Medical ( NYSE:GMED )
AUDUBON, Pa., July 15, 2025 ( GLOBE NEWSWIRE ) -- Globus Medical, Inc. GMED, a leading musculoskeletal solutions company, today announced the expanded Excelsius™ navigation capabilities of its next-generation oscillating system, DuraPro™, as the latest addition to the Power Portfolio, designed to ...
Globus Medical Introduces DuraPro™ with Navigation, a Next-Generation, Oscillating System Designed to Safeguard Delicate Tissue
AUDUBON, Pa., July 15, 2025 ( GLOBE NEWSWIRE ) -- Globus Medical, Inc. ( NYSE: GMED ) , a leading musculoskeletal solutions company, today announced the expanded Excelsius™ navigation capabilities of its next-generation oscillating system, DuraPro™, as the latest addition to the Power Portfolio, ...
iRhythm Technologies Announces Board Member Retirements and New Director Appointments
SAN FRANCISCO, July 07, 2025 ( GLOBE NEWSWIRE ) -- iRhythm Technologies, Inc. ( NASDAQ:IRTC ) , a leading digital health care company focused on creating trusted solutions that detect, predict, and prevent disease, today announced the retirement of two long-serving board members, Mark Rubash and ...
iRhythm Technologies Announces Board Member Retirements and New Director Appointments - Absci ( NASDAQ:ABSI ) , Alphatec Holdings ( NASDAQ:ATEC )
SAN FRANCISCO, July 07, 2025 ( GLOBE NEWSWIRE ) -- iRhythm Technologies, Inc. IRTC , a leading digital health care company focused on creating trusted solutions that detect, predict, and prevent disease, today announced the retirement of two long-serving board members, Mark Rubash and Ralph ...
Can ISRG Maintain Robotics Edge Amid Rising Rivalry & Budget Strain?
ISRG posted strong Q1 growth, but rising rivals and tighter hospital budgets test its robotics dominance and pricing power.
Price Over Earnings Overview: Globus Medical - Globus Medical ( NYSE:GMED )
In the current session, Globus Medical Inc. GMED is trading at $58.35, after a 0.53% decrease. Over the past month, the stock fell by 1.45%, and in the past year, by 15.25%. With performance like this, long-term shareholders are more likely to start looking into the company's price-to-earnings ...
Is the Market Bullish or Bearish on Globus Medical? - Globus Medical ( NYSE:GMED )
Globus Medical's GMED short percent of float has risen 14.54% since its last report. The company recently reported that it has 5.16 million shares sold short, which is 5.12% of all regular shares that are available for trading.
Intuitive Surgical's da Vinci 5: Gaining Precision, Power and Potential
ISRG's da Vinci 5 is gaining momentum with key innovations like Force Feedback and strong Q1 placements boosting adoption.
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims on Behalf of Investors of Globus Medical, Inc. - GMED - Globus Medical ( NYSE:GMED )
NEW YORK, June 02, 2025 ( GLOBE NEWSWIRE ) -- Pomerantz LLP is investigating claims on behalf of investors of Globus Medical, Inc. ( "Globus" or the "Company" ) GMED. Such investors are advised to contact Danielle Peyton at [email protected] or 646-581-9980, ext. 7980.
A Look Into Globus Medical Inc's Price Over Earnings - Globus Medical ( NYSE:GMED )
In the current session, Globus Medical Inc. GMED is trading at $59.40, after a 0.32% drop. Over the past month, the stock fell by 17.24%, and in the past year, by 10.80%. With performance like this, long-term shareholders are more likely to start looking into the company's price-to-earnings ratio.
This United States Steel Analyst Is No Longer Bullish; Here Are Top 3 Downgrades For Tuesday - Globus Medical ( NYSE:GMED ) , Unity Biotechnology ( NASDAQ:UBX )
Top Wall Street analysts changed their outlook on these top names. For a complete view of all analyst rating changes, including upgrades, downgrades and initiations, please see our analyst ratings page. HC Wainwright & Co. analyst Matthew Caufield downgraded Unity Biotechnology, Inc.
Globus Medical Announces $500 Million Share Repurchase Program
AUDUBON, Pa., May 15, 2025 ( GLOBE NEWSWIRE ) -- Globus Medical, Inc. ( NYSE: GMED ) , a leading musculoskeletal solutions company, today announced that its Board of Directors has authorized a share repurchase program of up to $500 million of the Company's outstanding common stock.
Outset Medical Appoints Industry Veteran Kevin O'Boyle to its Board of Directors
SAN JOSE, Calif., May 14, 2025 ( GLOBE NEWSWIRE ) -- Outset Medical, Inc. ( Nasdaq: OM ) ( "Outset" ) , a medical technology company pioneering a first-of-its-kind technology to reduce the cost and complexity of dialysis, today announced the appointment of healthcare industry veteran Kevin ...
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims on Behalf of Investors of Globus Medical, Inc. - GMED - Globus Medical ( NYSE:GMED )
NEW YORK, May 13, 2025 ( GLOBE NEWSWIRE ) -- Pomerantz LLP is investigating claims on behalf of investors of Globus Medical, Inc. ( "Globus" or the "Company" ) GMED. Such investors are advised to contact Danielle Peyton at [email protected] or 646-581-9980, ext. 7980.
GMED Q1 Earnings & Revenues Miss, '25 EPS View Down, Stock Falls
GMED's first-quarter 2025 weak performance reflects soft Enabling Technology deal closures.
Expedia, Wolfspeed, HubSpot And Other Big Stocks Moving Lower In Friday's Pre-Market Session - Expedia Group ( NASDAQ:EXPE ) , Affirm Holdings ( NASDAQ:AFRM )
U.S. stock futures were higher this morning, with the Nasdaq futures gaining around 0.5% on Friday. Shares of Expedia Group, Inc. EXPE fell sharply in today's pre-market trading after the company reported worse-than-expected Q1 sales results.
Why Pinterest Shares Are Trading Higher By 13%; Here Are 20 Stocks Moving Premarket - Corvus Pharma ( NASDAQ:CRVS ) , Clean Energy Technologies ( NASDAQ:CETY )
Shares of Pinterest, Inc. PINS rose sharply in today's pre-market trading after the company reported better-than-expected first-quarter sales results and issued second-quarter sales guidance with its midpoint above estimates. Also, Pinterest's reported an increase in its monthly average users.
Globus Medical ( GMED ) Lags Q1 Earnings and Revenue Estimates
Globus Medical (GMED) delivered earnings and revenue surprises of -8.11% and 4.81%, respectively, for the quarter ended March 2025. Do the numbers hold clues to what lies ahead for the stock?
Globus Medical Reports First Quarter 2025 Results
AUDUBON, Pa., May 08, 2025 ( GLOBE NEWSWIRE ) -- Globus Medical, Inc. ( NYSE: GMED ) , a leading musculoskeletal solutions company, today announced its financial results for the quarter ended March 31, 2025.
RxSight, Inc. ( RXST ) Reports Q1 Loss, Tops Revenue Estimates
RxSight (RXST) delivered earnings and revenue surprises of 25% and 0.01%, respectively, for the quarter ended March 2025. Do the numbers hold clues to what lies ahead for the stock?
Neuronetics ( STIM ) Reports Q1 Loss, Tops Revenue Estimates
Neuronetics (STIM) delivered earnings and revenue surprises of -61.54% and 9.37%, respectively, for the quarter ended March 2025. Do the numbers hold clues to what lies ahead for the stock?
Should Invesco S&P MidCap 400 Pure Growth ETF ( RFG ) Be on Your Investing Radar?
Style Box ETF report for ...
Gear Up for Globus Medical ( GMED ) Q1 Earnings: Wall Street Estimates for Key Metrics
Beyond analysts' top -and-bottom-line estimates for Globus Medical (GMED), evaluate projections for some of its key metrics to gain a better insight into how the business might have performed for the quarter ended March 2025.
Alphatec ( ATEC ) Reports Q1 Loss, Tops Revenue Estimates
Alphatec (ATEC) delivered earnings and revenue surprises of -91.67% and 0.23%, respectively, for the quarter ended March 2025. Do the numbers hold clues to what lies ahead for the stock?
Globus Medical ( GMED ) Earnings Expected to Grow: Should You Buy?
Globus Medical (GMED) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
4 MedTech Stocks Poised to Outshine Q1 Earnings Estimates
MedTech companies' quarterly results are likely to reflect base business recovery on a year-over-year basis. Let's see how HIMS, GMED, QDRL and HAE are poised ahead of their earnings release.
Strong Segmental Performance to Drive Stryker's Q1 Earnings?
SYK's first-quarter 2025 results are expected to reflect strong segmental performance. However, rising costs are likely to have continued to hurt margins.
DXCM Q1 Earnings to Reflect U.S. Coverage Expansion & Stelo Impact?
DexCom Q1 results are likely to reflect strong growth on the back of coverage by two large PBMs and Stelo traction, driving momentum and market expansion in 2025.
Will BAX's Q1 Earnings Improve Following Transformation Completion?
Baxter's first-quarter results are likely to reflect the favorable impact of kidney care sales. Growth in infusion therapies, pharmaceuticals and patient support systems to continue.
What Does the Market Think About Globus Medical? - Globus Medical ( NYSE:GMED )
Globus Medical's GMED short percent of float has risen 36.6% since its last report. The company recently reported that it has 3.30 million shares sold short, which is 3.21% of all regular shares that are available for trading.
Segmental Performance to Drive RVTY's Q1 Earnings: Is a Beat Likely?
RVTY's first-quarter results are likely to reflect decent performance in the Diagnostics segment. The Life Sciences segment is likely to have faced continued challenges in China.
